Stocks of Altimmune Inc (NASDAQ:ALT) traded higher last session on Wall Street, down -19.75% to $5.20.
According to the data, Altimmune Inc (NASDAQ:ALT) has 7 analysts covering its stock. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $35.00 and a low of $15.00, we find $25.00. Given the previous closing price of $6.48, this indicates a potential upside of 285.8 percent. ALT stock price is now 77.46% away from the 50-day moving average and 24.52% away from the 200-day moving average. The market capitalization of the company currently stands at $279.40M.
A total of 0 analysts have issued a hold rating and 7 have given it a buy rating. Brokers who have rated the stock have averaged $22.29 as their price target over the next twelve months.
With the price target reduced from $20 to $6, Goldman Downgraded its rating from Buy to Neutral for Altimmune Inc (NASDAQ: ALT).
In other news, Drutz David, Director bought 300 shares of the company’s stock on Aug 15. The stock was bought for $862 at an average price of $2.88. Upon completion of the transaction, the Director now directly owns 29,785 shares in the company, valued at $0.15 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 24, Chief Financial Officer Eisenstadt Richard I bought 10,000 shares of the business’s stock. A total of $43,140 was incurred on buying the stock at an average price of $4.31. This leaves the insider owning 22,010 shares of the company worth $0.11 million. Insiders disposed of 48,213 shares of company stock worth roughly $0.25 million over the past 1 year. A total of 1.01% of the company’s stock is owned by insiders.
Monday’s opening bell rang with an opening price of $6.72 for Altimmune Inc (NASDAQ: ALT). During the past 12 months, Altimmune Inc has had a low of $2.09 and a high of $17.17. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 12.89, and a quick ratio of 12.89. The fifty day moving average price for ALT is $2.93 and a two-hundred day moving average price translates $4.18 for the stock.
The latest earnings results from Altimmune Inc (NASDAQ: ALT) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.39, beating analysts’ expectations of -$0.42 by 0.03. This compares to -$0.48 EPS in the same period last year. The net profit margin was -28124.01% and return on equity was -44.15% for ALT. The company reported revenue of $0.36 million for the quarter, compared to $2000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 18000.0 percent.
Altimmune Inc(ALT) Company Profile
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
